Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVERMECTIN vs EMVERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
FDA-approved: Treatment of onchocerciasis (river blindness), strongyloidiasis, and intestinal infections caused by Strongyloides stercoralis.,FDA-approved: Scabies (topical formulation).,Off-label: Treatment of other parasitic infections including ascariasis, trichuriasis, enterobiasis, filariasis, loiasis, and cutaneous larva migrans.,Off-label: Treatment of severe, refractory, or crusted scabies (oral).,Off-label: Used in combination with albendazole for lymphatic filariasis.,Investigational: Used for scabies in institutional settings and for rosacea (topical).
Treatment of trichuriasis (whipworm infection),Treatment of enterobiasis (pinworm infection),Treatment of ascariasis (roundworm infection),Treatment of hookworm infections (Ancylostoma duodenale and Necator americanus),Off-label: Treatment of capillariasis, toxocariasis, and other helminth infections
150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Terminal elimination half-life is approximately 18 hours (range 12-24 hours) in healthy adults; prolonged in hepatic impairment.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Ivermectin is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4. It is also a substrate of P-glycoprotein (P-gp).
Primarily hepatic; metabolized by microsomal enzymes (CYP450) to major metabolite 2-aminomebendazole, which is less active; also undergoes further metabolism.
Primarily fecal (≥90% as unchanged drug and metabolites); renal excretion is minimal (<1% of dose). Biliary excretion contributes to fecal elimination.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Approximately 93% bound to plasma proteins, primarily albumin and possibly alpha-1-acid glycoprotein.
~90-95% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is 3.1-3.5 L/kg (large, indicating extensive tissue distribution including fat and skin).
~1-2 L/kg; indicates extensive tissue distribution.
Oral bioavailability is approximately 60-80% (due to extensive first-pass metabolism). Topical bioavailability is negligible (<1% systemic absorption).
Oral: ~22-40% due to first-pass metabolism; improved with food.
No dose adjustment required for any degree of renal impairment.
No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Use with caution in severe hepatic impairment; specific Child-Pugh-based dosing not established.
No adjustment for mild (Child-Pugh A) or moderate (Child-Pugh B) impairment. Avoid use in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Weight-based: 150–200 mcg/kg orally once, same as adult; safety for children weighing less than 15 kg not established.
Children ≥2 years: 100 mg orally twice daily for 3 days. Children <2 years: safety not established; use only if potential benefit outweighs risk.
No specific dose adjustment; monitor for adverse effects due to potential age-related organ dysfunction.
No specific adjustment required; use standard adult dosing. Monitor for adverse effects due to potential age-related renal or hepatic decline.
No FDA black box warnings.
None.
Severe skin reactions (Mazzotti reaction) when treating onchocerciasis, including pruritus, urticaria, fever, arthralgias, syncope, and lymphadenitis.,Neurological toxicity in high doses or with compromised blood-brain barrier (e.g., due to meningitis, African trypanosomiasis, or Loa loa infection with high microfilarial loads).,Ocular reactions in onchocerciasis: exacerbation of eye lesions, including optic neuritis and chorioretinitis.,Potential for drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) or P-gp inhibitors (e.g., verapamil, cyclosporine), leading to increased ivermectin exposure.,Hypersensitivity reactions.,Use in pregnancy only if clearly needed (data limited).,Not recommended in children under 5 years of age or weighing less than 15 kg.
Risk of neutropenia and agranulocytosis, especially with high doses or prolonged use,May cause bone marrow suppression; monitor blood counts in prolonged therapy,Hepatotoxicity reported; use caution in hepatic impairment,Seizures have occurred, particularly in patients with history of seizures,Not recommended in pregnancy (pregnancy category C); embryotoxic and teratogenic in animals
Hypersensitivity to ivermectin or any component of the formulation.,Concurrent use with drugs that inhibit CYP3A4 or P-gp may require caution, but absolute contraindication is rare.,Loa loa infection with high microfilarial loads (risk of severe encephalopathy).
Hypersensitivity to mebendazole or any component of the formulation,Absolute contraindication: Known hypersensitivity
Ivermectin should be taken on an empty stomach with water. Administration with food, particularly high-fat meals, can significantly increase absorption (up to 2.5-fold), potentially increasing the risk of adverse effects. Therefore, avoid food for at least 2 hours before and 1 hour after dosing. Grapefruit juice may inhibit CYP3A4 and could theoretically increase ivermectin levels; caution is advised.
No significant food interactions; absorption is enhanced by fatty foods but not required for efficacy in enterobiasis. Avoid alcohol due to potential hepatotoxicity.
FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in second/third trimester from observational studies.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed. Risk cannot be ruled out, especially in the first trimester.
Ivermectin is excreted into breast milk; M/P ratio unknown. Limited human data suggests low levels. Caution in infants weighing <15 kg due to potential CNS effects. Consider temporary cessation of breastfeeding during therapy.
Excretion in human milk unknown. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
Pharmacokinetics in pregnancy not well studied. No recommended dose adjustments. Use standard weight-based dosing (150–200 mcg/kg) but avoid in first trimester unless essential.
No dose adjustment is recommended solely due to pregnancy, as pharmacokinetic changes are not well characterized. Use standard dosing: mebendazole 100 mg twice daily for 3 days for pinworm (or single 100 mg dose). For other indications, follow standard protocols.
Ivermectin is a broad-spectrum antiparasitic agent that causes parasite death by increasing chloride ion conductance in invertebrate nerve and muscle cells. It is the drug of choice for onchocerciasis and strongyloidiasis, and is also used for scabies and head lice. For onchocerciasis, it is given as a single dose of 150 mcg/kg, repeated every 6-12 months. For strongyloidiasis, the recommended dose is 200 mcg/kg daily for 2 days. For crusted scabies, multiple doses (e.g., on days 1, 2, 8, 9) may be required. Note: Ivermectin does not kill adult Onchocerca worms but reduces microfilarial load. Severe adverse effects (Mazzotti reaction) can occur in onchocerciasis due to rapid microfilarial killing. Avoid in patients with Loa loa co-infection due to risk of encephalopathy. Ivermectin is not recommended for children under 15 kg or pregnant women unless benefits outweigh risks. Drug interactions: caution with CYP3A4 inhibitors or inducers; consider dose adjustment with strong inhibitors like ketoconazole.
EMVERM (mebendazole) is poorly absorbed systemically, making it ideal for intraluminal helminth infections. Administer with fatty meal to enhance absorption when systemic effect (e.g., for trichinosis) is desired. Avoid in pregnancy (FDA Category C). Tablets may be chewed, swallowed, or crushed. Monitor for rare agranulocytosis, especially with concurrent metronidazole or high doses.
Take ivermectin exactly as prescribed, usually on an empty stomach with water.,For strongyloidiasis or scabies, you may need a second dose; complete the full course.,Do not take with food, especially high-fat meals, as they may increase absorption and risk of side effects.,Common side effects include dizziness, pruritus, and gastrointestinal upset.,Report any severe skin rash, swelling, or difficulty breathing immediately.,If being treated for onchocerciasis, you may experience a reaction (fever, itching, joint pain) due to dying parasites; this is usually mild and treatable.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Inform your doctor if you are pregnant, breastfeeding, or taking other medications.,Do not use ivermectin for COVID-19; it is not approved for viral infections.
Take exactly as prescribed; a second course may be needed if reinfection occurs.,Tablets can be chewed, crushed, or swallowed whole with or without food.,Mebendazole works by preventing worms from absorbing sugar, causing their death.,Strict hand hygiene and laundering of bedding/clothing to prevent reinfection.,Treat all household members if pinworm outbreak; withhold treatment in pregnancy unless essential.,Notify provider if fever, sore throat, or unusual bleeding/bruising (agranulocytosis warning).
"Coadministration of ivermectin, a known inhibitor of cytochrome P450 3A4 (CYP3A4), with netupitant, a CYP3A4 substrate, can result in increased systemic exposure to netupitant. This may potentiate netupitant-related adverse effects, such as nausea, fatigue, and QT prolongation, particularly in patients with underlying hepatic impairment or those receiving other QT-prolonging agents."
"Ivermectin is a substrate of CYP3A4 and P-glycoprotein (P-gp), while imatinib is primarily metabolized by CYP3A4 and is also a substrate of P-gp. Concomitant administration of ivermectin may competitively inhibit CYP3A4 and P-gp, reducing the clearance of imatinib and increasing its systemic exposure. This can potentiate imatinib's adverse effects, including hepatotoxicity, fluid retention, and myelosuppression, particularly at high doses."
"Ivermectin is a moderate inhibitor of CYP3A4, the primary enzyme responsible for simeprevir metabolism. Concomitant administration significantly reduces simeprevir clearance, leading to elevated plasma concentrations. This increases the risk of simeprevir-related adverse effects, including hepatotoxicity, QT prolongation, and rash."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVERMECTIN vs EMVERM, answered by our medical review team.
IVERMECTIN is a Anthelmintic that works by Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.. EMVERM is a Anthelmintic that works by Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVERMECTIN and EMVERM depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVERMECTIN is: 150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.. The standard adult dose of EMVERM is: Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVERMECTIN and EMVERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVERMECTIN is classified as Category A/B. FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in seco. EMVERM is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.